Status:

TERMINATED

Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin

Lead Sponsor:

Mayo Clinic

Conditions:

Breast Pain

Non-cyclical Mastalgia

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The study was a randomized, double-blinded, crossover trial of topical diclofenac and placebo (10 weeks of each) for the treatment of noncyclic breast pain.

Detailed Description

A prospective, randomized, double-blinded crossover trial comparing topical diclofenac and placebo for 10 weeks in the treatment of 30 women with noncyclic mastalgia and surgical scar-related breast p...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Noncyclic mastalgia or surgical scar-related pain occurring at least 2 days per week and for which the patient desires treatment
  • Duration of pain \> 2 months (noncyclic mastalgia) or \> 4 months (surgical scar-related pain)
  • Age \> 18 years
  • Satisfactory breast examination and directed ultrasound at site of pain (all ages) within 12 months
  • Satisfactory mammogram (all women \> 30 years of age) within 12 months
  • Negative pregnancy test (all women who are premenopausal and have not had hysterectomy or tubal ligation)
  • Exclusion criteria
  • Cyclic mastalgia (as defined above)
  • Duration of pain \> 2 months (noncyclic mastalgia) or \> 4 months (surgical scar-related pain)
  • Abnormal breast examination or imaging (abnormality at the site of pain or for which biopsy or surgical consultation is recommended)
  • Known pregnancy, lactation, positive pregnancy test, or anticipated pregnancy within 6 months
  • Asthma, that has been aggravated by oral nonsteroidal antiinflammatory agents
  • Allergy, to diclofenac or any nonsteroidal antiinflammatory agents
  • Rash or open lesions at the site on the breast where the topical agent would be applied
  • Incomplete or abnormal healing (surgical scar-related pain)
  • History of gastrointestinal ulceration, renal dysfunction (creatinine \> 1.5), hepatic disease (known liver disease or aspartate aminotransferase (AST) twice normal levels), congestive heart failure and uncontrolled hypertension (blood pressure \> 140/90)

Exclusion

    Key Trial Info

    Start Date :

    June 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2009

    Estimated Enrollment :

    25 Patients enrolled

    Trial Details

    Trial ID

    NCT00276419

    Start Date

    June 1 2005

    End Date

    May 1 2009

    Last Update

    December 20 2012

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Mayo Clinic

    Rochester, Minnesota, United States, 55905